Hyaluronic acid-conjugated lipid nanocarriers in advancing cancer therapy: A review.

Lipid nanoparticles are getting a lot of attention in cancer treatment because they're good at delivering drugs and reducing side effects. These things are like a flexible platform for getting anticancer meds where they need to go, especially when you add HA, a polymer that's known to target tumors. Hyaluronic acid is good because it homes in on tumor cells by latching onto CD44 receptors, which are often overproduced in cancer. Lipid nanoparticles do not just make drugs more soluble and stable; they also use the EPR effect, meaning they build up more in tumor tissue than in healthy tissue. Adding HA to these nanoparticles expands their biocompatibility and makes them more accurate. Studies show that HA-modified nanoparticles carrying drugs like paclitaxel or doxorubicin improve how well cells absorb the drugs, reduce drug resistance, and make tumors shrink better. These nanoparticles can respond to tumor microenvironment stimuli in targeted delivery. This targeted delivery cuts down on side effects and improves how well the drugs work overall. Thus, lipid-based nanoparticles with HA are a promising way to treat cancer by delivering drugs effectively, minimizing side effects, and giving us better results.